Biologics in current therapy for inflammatory bowel disease

Tadakazu Hisamatsu, Toshifumi Hibi

Research output: Contribution to journalArticle

Abstract

Recent advance of molecular biology and immunology contributes to the development biologics such as anti-TNFα agent in the treatment for inflammatory bowel disease (IBD). Although therapeutic strategy of IBD has not been changed for a long time, success of Infliximab, first anti-TNFα agent, now changes therapeutic strategy of IBD dramatically. Top-down strategy has been considered to improve patients' natural history in the therapy for Crohn's disease as well as in rheumatoid arthritis. Infliximab also has been expected as a promising medicine for pediatric Crohn's disease. Furthermore, Infliximab has been approved for the therapy of ulcerative colitis. These tremendous successes of Infliximab have encouraged us to develop other anti-TNF agents and other biologics. In this review, we describe current topics of biologics in IBD treatment and discuss future direction.

Original languageEnglish
Pages (from-to)168-179
Number of pages12
JournalJapanese Journal of Clinical Immunology
Volume32
Issue number3
DOIs
Publication statusPublished - 2009

Fingerprint

Biological Products
Inflammatory Bowel Diseases
Therapeutics
Biological Factors
Allergy and Immunology
Natural History
Ulcerative Colitis
Crohn Disease
Molecular Biology
Rheumatoid Arthritis
Medicine
Infliximab

Keywords

  • Biologics
  • Inflammatory bowel disease
  • TNFα

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Biologics in current therapy for inflammatory bowel disease. / Hisamatsu, Tadakazu; Hibi, Toshifumi.

In: Japanese Journal of Clinical Immunology, Vol. 32, No. 3, 2009, p. 168-179.

Research output: Contribution to journalArticle

Hisamatsu, Tadakazu ; Hibi, Toshifumi. / Biologics in current therapy for inflammatory bowel disease. In: Japanese Journal of Clinical Immunology. 2009 ; Vol. 32, No. 3. pp. 168-179.
@article{b25c7d6f53ec4b48b42013346c699f26,
title = "Biologics in current therapy for inflammatory bowel disease",
abstract = "Recent advance of molecular biology and immunology contributes to the development biologics such as anti-TNFα agent in the treatment for inflammatory bowel disease (IBD). Although therapeutic strategy of IBD has not been changed for a long time, success of Infliximab, first anti-TNFα agent, now changes therapeutic strategy of IBD dramatically. Top-down strategy has been considered to improve patients' natural history in the therapy for Crohn's disease as well as in rheumatoid arthritis. Infliximab also has been expected as a promising medicine for pediatric Crohn's disease. Furthermore, Infliximab has been approved for the therapy of ulcerative colitis. These tremendous successes of Infliximab have encouraged us to develop other anti-TNF agents and other biologics. In this review, we describe current topics of biologics in IBD treatment and discuss future direction.",
keywords = "Biologics, Inflammatory bowel disease, TNFα",
author = "Tadakazu Hisamatsu and Toshifumi Hibi",
year = "2009",
doi = "10.2177/jsci.32.168",
language = "English",
volume = "32",
pages = "168--179",
journal = "Immunological Medicine",
issn = "0911-4300",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Biologics in current therapy for inflammatory bowel disease

AU - Hisamatsu, Tadakazu

AU - Hibi, Toshifumi

PY - 2009

Y1 - 2009

N2 - Recent advance of molecular biology and immunology contributes to the development biologics such as anti-TNFα agent in the treatment for inflammatory bowel disease (IBD). Although therapeutic strategy of IBD has not been changed for a long time, success of Infliximab, first anti-TNFα agent, now changes therapeutic strategy of IBD dramatically. Top-down strategy has been considered to improve patients' natural history in the therapy for Crohn's disease as well as in rheumatoid arthritis. Infliximab also has been expected as a promising medicine for pediatric Crohn's disease. Furthermore, Infliximab has been approved for the therapy of ulcerative colitis. These tremendous successes of Infliximab have encouraged us to develop other anti-TNF agents and other biologics. In this review, we describe current topics of biologics in IBD treatment and discuss future direction.

AB - Recent advance of molecular biology and immunology contributes to the development biologics such as anti-TNFα agent in the treatment for inflammatory bowel disease (IBD). Although therapeutic strategy of IBD has not been changed for a long time, success of Infliximab, first anti-TNFα agent, now changes therapeutic strategy of IBD dramatically. Top-down strategy has been considered to improve patients' natural history in the therapy for Crohn's disease as well as in rheumatoid arthritis. Infliximab also has been expected as a promising medicine for pediatric Crohn's disease. Furthermore, Infliximab has been approved for the therapy of ulcerative colitis. These tremendous successes of Infliximab have encouraged us to develop other anti-TNF agents and other biologics. In this review, we describe current topics of biologics in IBD treatment and discuss future direction.

KW - Biologics

KW - Inflammatory bowel disease

KW - TNFα

UR - http://www.scopus.com/inward/record.url?scp=77953672014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953672014&partnerID=8YFLogxK

U2 - 10.2177/jsci.32.168

DO - 10.2177/jsci.32.168

M3 - Article

VL - 32

SP - 168

EP - 179

JO - Immunological Medicine

JF - Immunological Medicine

SN - 0911-4300

IS - 3

ER -